Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Operating Margin (2016 - 2025)

Plus Therapeutics has reported Operating Margin over the past 13 years, most recently at 420.04% for Q4 2025.

  • Quarterly Operating Margin fell 14384.0% to 420.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 293.46% through Dec 2025, down 4114.0% year-over-year, with the annual reading at 293.46% for FY2025, 4114.0% down from the prior year.
  • Operating Margin was 420.04% for Q4 2025 at Plus Therapeutics, down from 320.83% in the prior quarter.
  • Over five years, Operating Margin peaked at 73.89% in Q3 2023 and troughed at 6978.08% in Q3 2022.
  • The 4-year median for Operating Margin is 291.44% (2023), against an average of 1068.08%.
  • Year-over-year, Operating Margin surged 690420bps in 2023 and then crashed -21063bps in 2024.
  • A 4-year view of Operating Margin shows it stood at 4387.4% in 2022, then surged by 93bps to 293.83% in 2023, then increased by 6bps to 276.2% in 2024, then plummeted by -52bps to 420.04% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Operating Margin are 420.04% (Q4 2025), 320.83% (Q3 2025), and 110.65% (Q2 2025).